{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T22:33:32Z","timestamp":1791758012261,"version":"4.3.4"},"reference-count":13,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2000,3,1]],"date-time":"2000-03-01T00:00:00Z","timestamp":951868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2000,3,1]],"date-time":"2000-03-01T00:00:00Z","timestamp":951868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":4886,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2000,3]]},"DOI":"10.1053\/seiz.2000.0380","type":"journal-article","created":{"date-parts":[[2002,7,28]],"date-time":"2002-07-28T17:49:59Z","timestamp":1027878599000},"page":"80-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":199,"title":["A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy"],"prefix":"10.1053","volume":"9","author":[{"given":"T","family":"Betts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Waegemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/seiz.2000.0380_RF1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2125.1996.tb00046.x","article-title":"The new generation of antiepileptic drugs: advantages and disadvantages","volume":"42","author":"Perucca","year":"1996","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1053\/seiz.2000.0380_RF2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM198507183130303","article-title":"Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures","volume":"313","author":"Mattson","year":"1985","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/seiz.2000.0380_RF3","first-page":"1067","article-title":"New drugs for the treatment of epilepsy","volume":"2","author":"L\u00f6scher","year":"1993","journal-title":"Current Opinion Investigating Drugs"},{"key":"10.1053\/seiz.2000.0380_RF4","series-title":"Tolerance to Beneficial and Adverse Effects of Antiepileptic Drugs. (Eds W. P. Koella et al.)","article-title":"Early tolerance to antiepileptic drug side effects: a controlled trial of 247 patients","author":"Mattson","year":"1986"},{"key":"10.1053\/seiz.2000.0380_RF5","series-title":"Meyler\u2019s Side Effects of Drugs. 12thedition","first-page":"122","article-title":"Anticonvulsants","author":"Schmidt","year":"1992"},{"key":"10.1053\/seiz.2000.0380_RF6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0014-2999(93)90768-D","article-title":"Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats","volume":"32","author":"L\u00f6scher","year":"1993","journal-title":"European Journal of Pharmacoogy"},{"key":"10.1053\/seiz.2000.0380_RF7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0014-2999(98)00410-5","article-title":"Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy","volume":"353","author":"Klitgaard","year":"1998","journal-title":"European Journal of Pharmacology"},{"key":"10.1053\/seiz.2000.0380_RF8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0920-1211(95)00077-1","article-title":"Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy","volume":"22","author":"Gower","year":"1995","journal-title":"Epilepsy Research"},{"key":"10.1053\/seiz.2000.0380_RF9","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-3565(24)37251-9","article-title":"Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy","volume":"284","author":"L\u00f6scher","year":"1998","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1053\/seiz.2000.0380_RF10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0014-2999(95)00436-O","article-title":"The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes","volume":"286","author":"Noyer","year":"1995","journal-title":"European Journal of Pharmacology"},{"key":"10.1053\/seiz.2000.0380_RF11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2165\/00003088-199631010-00003","article-title":"The clinical pharmacokinetics of the newer antiepileptic drugs: focus on topiramate, zonisamide, and tiagabine","volume":"31","author":"Perucca","year":"1996","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1053\/seiz.2000.0380_RF13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/0896-6974(96)00010-2","article-title":"Efficacy and tolerability study of ucb L059 in patients with refractory epilepsy","volume":"9","author":"Sharief","year":"1996","journal-title":"Journal of Epilepsy"},{"key":"10.1053\/seiz.2000.0380_RF14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","volume":"22","year":"1981","journal-title":"Epilepsia"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131100903807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131100903807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:25:15Z","timestamp":1761009915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131100903807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,3]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,3]]}},"alternative-id":["S1059131100903807"],"URL":"https:\/\/doi.org\/10.1053\/seiz.2000.0380","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2000,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/seiz.2000.0380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2000 BEA Trading, Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}